| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
-Linolenic Acid-Enriched Diet Prevents Myocardial Damage and Expands Longevity in Cardiomyopathic Hamsters









From the Laboratorio di Cardiologia Molecolare e Cellulare* and Medicina Molecolare,|| the Dipartimento di Medicina Interna, and the Dipartimento di Medicina Sperimentale e Scienze Biochimiche,¶ Università di Roma Tor Vergata, Roma; the Istituto Nazionale per la Ricerca Cardiovascolare,
Bologna; the Dipartimento di Medicina Sperimentale e Patologia,
Università di Roma la Sapienza, Roma; the Dipartimento di Medicina Interna,
Sezione di Biochimica, Università di Perugia, Perugia; Syntech srl,** Roma; and the Istituto di Medicina Interna e Geriatria,
Università Cattolica S. Cuore, Roma, Italy
Randomized clinical trials have demonstrated that the increased intake of
-3 polyunsaturated fatty acids significantly reduces the risk of ischemic cardiovascular disease, but no investigations have been performed in hereditary cardiomyopathies with diffusely damaged myocardium. In the present study,
-sarcoglycan-null cardiomyopathic hamsters were fed from weaning to death with an
-linolenic acid (ALA)-enriched versus standard diet. Results demonstrated a great accumulation of ALA and eicosapentaenoic acid and an increased eicosapentaenoic/arachidonic acid ratio in cardiomyopathic hamster hearts, correlating with the preservation of myocardial structure and function. In fact, ALA administration preserved plasmalemma and mitochondrial membrane integrity, thus maintaining proper cell/extracellular matrix contacts and signaling, as well as a normal gene expression profile (myosin heavy chain isoforms, atrial natriuretic peptide, transforming growth factor-ß1) and a limited extension of fibrotic areas within ALA-fed cardiomyopathic hearts. Consequently, hemodynamic indexes were safeguarded, and more than 60% of ALA-fed animals were still alive (mean survival time, 293 ± 141.8 days) when all those fed with standard diet were deceased (mean survival time, 175.9 ± 56 days). Therefore, the clinically evident beneficial effects of
-3 polyunsaturated fatty acids are mainly related to preservation of myocardium structure and function and the attenuation of myocardial fibrosis.
This article has been cited by other articles:
![]() |
M. K. Duda, K. M. O'Shea, and W. C. Stanley {omega}-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential Cardiovasc Res, June 20, 2009; (2009) cvp169v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
Vet. Pathol., May 1, 2007; 44(3): 422 - 422. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |